BR112017008198A2 - pró-fármacos de carbidopa e l-dopa e métodos de uso - Google Patents

pró-fármacos de carbidopa e l-dopa e métodos de uso

Info

Publication number
BR112017008198A2
BR112017008198A2 BR112017008198A BR112017008198A BR112017008198A2 BR 112017008198 A2 BR112017008198 A2 BR 112017008198A2 BR 112017008198 A BR112017008198 A BR 112017008198A BR 112017008198 A BR112017008198 A BR 112017008198A BR 112017008198 A2 BR112017008198 A2 BR 112017008198A2
Authority
BR
Brazil
Prior art keywords
carbidopa
methods
dopa
prodrug
prodrugs
Prior art date
Application number
BR112017008198A
Other languages
English (en)
Other versions
BR112017008198B1 (pt
Inventor
D Huters Alexander
Cardinal-David Benoit
P Enright Brian
P Miller Christopher
A Voight Eric
G Zhang Geoff
Stambuli James
E Dempah Kassibla
A Matulenko Mark
T Mayer Peter
R Kym Philip
Ho Raimundo
F Henry Rodger
C Klix Russell
W Krabbe Scott
E Mackey Sean
J Stella Valentino
S Chan Vincent
Lou Xiaochun
Lao Yanbin
Huang Ye
Wang Zhi
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017008198(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112017008198A2 publication Critical patent/BR112017008198A2/pt
Publication of BR112017008198B1 publication Critical patent/BR112017008198B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

resumo ?pró-fármacos de carbidopa e l-dopa e métodos de uso? a presente divulgação refere-se a (a) pró-fármacos de carbidopa, (b) combinações e composições farmacêuticas compreendendo um pró-fármaco de carbidopa e/ou um pró-fármaco de l-dopa, e (c) métodos de tratar doença de parkinson e condições associadas compreendendo administrar um pró-fármaco de carbidopa e um pró-fármaco de l-dopa a um sujeito com doença de parkinson.
BR112017008198-9A 2014-10-21 2015-10-21 combinação farmacêutica compreendendo pró-fármacos de carbidopa e l-dopa e uso da mesma para a preparação de uma composição farmacêutica para tratar doença de parkinson BR112017008198B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
US62/066,771 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (2)

Publication Number Publication Date
BR112017008198A2 true BR112017008198A2 (pt) 2017-12-26
BR112017008198B1 BR112017008198B1 (pt) 2021-02-09

Family

ID=54478240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008198-9A BR112017008198B1 (pt) 2014-10-21 2015-10-21 combinação farmacêutica compreendendo pró-fármacos de carbidopa e l-dopa e uso da mesma para a preparação de uma composição farmacêutica para tratar doença de parkinson

Country Status (35)

Country Link
US (7) US9446059B2 (pt)
EP (3) EP3209302B1 (pt)
JP (5) JP6567049B2 (pt)
KR (3) KR20240113982A (pt)
CN (4) CN107206013A (pt)
AR (1) AR102389A1 (pt)
AU (3) AU2015335941B2 (pt)
BR (1) BR112017008198B1 (pt)
CA (1) CA2965379A1 (pt)
CY (2) CY1121826T1 (pt)
DK (1) DK3209302T3 (pt)
ES (1) ES2739536T3 (pt)
FI (1) FIC20230014I1 (pt)
FR (1) FR23C1035I1 (pt)
HR (1) HRP20191285T1 (pt)
HU (2) HUE044115T2 (pt)
IL (3) IL251829B (pt)
LT (2) LT3209302T (pt)
MX (2) MX2017005236A (pt)
MY (1) MY189519A (pt)
NL (1) NL301224I2 (pt)
NO (1) NO2023013I1 (pt)
PH (1) PH12017500746B1 (pt)
PL (1) PL3209302T3 (pt)
PT (1) PT3209302T (pt)
RS (1) RS58972B1 (pt)
RU (2) RU2021103000A (pt)
SA (1) SA521421115B1 (pt)
SG (1) SG11201703170RA (pt)
SI (1) SI3209302T1 (pt)
TR (1) TR201908296T4 (pt)
TW (2) TWI755257B (pt)
UA (1) UA120437C2 (pt)
WO (1) WO2016065019A1 (pt)
ZA (1) ZA201702760B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP4299128A3 (en) 2014-03-13 2024-04-17 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
PT3209302T (pt) * 2014-10-21 2019-07-19 Abbvie Inc Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson
US20190224220A1 (en) * 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
CA3028423A1 (en) 2016-06-22 2017-12-28 Medchem Partners, Llc. Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
SG11202004461YA (en) 2017-11-24 2020-06-29 H Lundbeck As New catecholamine prodrugs for use in the treatment of parkinson's disease
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
KR20210091139A (ko) * 2018-11-15 2021-07-21 애브비 인코포레이티드 피하 투여용 약제학적 제형
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ATE118216T1 (de) * 1989-04-20 1995-02-15 Zambon Spa Dopamin-medikament-vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
EP1030853A1 (en) * 1997-11-12 2000-08-30 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
NZ537686A (en) 2002-06-20 2007-01-26 Nippon Suisan Kaisha Ltd A beta2 agonist prodrug having reduced side effects
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
CA2536175C (en) 2003-08-29 2013-05-28 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
EP1677758A1 (en) 2003-10-31 2006-07-12 ALZA Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
ZA200610042B (en) * 2004-06-04 2008-06-25 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
EP1773850B1 (en) 2004-07-06 2013-01-30 Abbott Laboratories Prodrugs of hiv protease inhibitors
BRPI0619425A2 (pt) * 2005-12-05 2011-10-04 Xenoport Inc mesilato de pró-fármaco de levedopa, composição farmacêutica, método de preparar (2s)-2- amino-3-(3,4-diidróxi fenil) propanoato de mesilato de (2r)-2- fenil carbonilóxi propila e uso do referido composto
CA2653683A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa
EA014576B1 (ru) * 2006-06-16 2010-12-30 Солвей Фармасьютикалс Б.В. Комбинированные препараты, содержащие бифепрунокс и l-допу
WO2008076458A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
DK2432454T3 (en) 2009-05-19 2017-06-19 Neuroderm Ltd COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA DECARBOXYLASE INHIBITORS
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
PL3326615T3 (pl) 2010-11-15 2020-07-27 Neuroderm Ltd Ciągłe podawanie L-dopy, inhibitorów dekarboksylazy dopy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji
JP5423905B2 (ja) 2010-12-02 2014-02-19 小野薬品工業株式会社 新規化合物及びその医薬用途
AU2011341316A1 (en) 2010-12-10 2013-07-04 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
WO2012158527A2 (en) * 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
CN105209029A (zh) 2013-03-13 2015-12-30 纽罗德姆有限公司 帕金森病的治疗方法
MX2015012559A (es) 2013-03-15 2016-07-18 Techfields Pharma Co Ltd Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
PT3209302T (pt) 2014-10-21 2019-07-19 Abbvie Inc Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US20190224220A1 (en) 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
KR20240113982A (ko) 2024-07-23
ES2739536T3 (es) 2020-01-31
JP2017537066A (ja) 2017-12-14
NO2023013I1 (no) 2023-03-20
US20230106081A1 (en) 2023-04-06
RU2021103000A (ru) 2021-03-01
JP2021183628A (ja) 2021-12-02
US20160106765A1 (en) 2016-04-21
CY1121826T1 (el) 2020-07-31
AR102389A1 (es) 2017-02-22
MX2017005236A (es) 2017-07-26
CN111494395A (zh) 2020-08-07
AU2021201414B2 (en) 2023-05-11
US20200262852A1 (en) 2020-08-20
NL301224I1 (pt) 2023-03-29
WO2016065019A1 (en) 2016-04-28
CN107206013A (zh) 2017-09-26
US20180079762A1 (en) 2018-03-22
FR23C1035I1 (fr) 2023-12-08
US10730895B2 (en) 2020-08-04
DK3209302T3 (da) 2019-05-13
EP4186510A1 (en) 2023-05-31
CY2023010I1 (el) 2023-06-09
HUE044115T2 (hu) 2019-10-28
TWI718999B (zh) 2021-02-21
LTPA2023519I1 (pt) 2023-06-26
MX2021003840A (es) 2022-06-30
IL268885B (en) 2020-08-31
TR201908296T4 (tr) 2019-06-21
CN111494395B (zh) 2024-06-21
RU2017117413A3 (pt) 2019-05-30
TW201630924A (zh) 2016-09-01
US20160362431A1 (en) 2016-12-15
JP6567049B2 (ja) 2019-08-28
KR20170071599A (ko) 2017-06-23
SI3209302T1 (sl) 2019-06-28
RU2017117413A (ru) 2018-11-26
KR102537018B1 (ko) 2023-05-30
RU2743347C2 (ru) 2021-02-17
RS58972B1 (sr) 2019-08-30
TWI755257B (zh) 2022-02-11
HRP20191285T1 (hr) 2019-10-18
EP3569587A1 (en) 2019-11-20
IL276493A (en) 2020-09-30
JP6750076B2 (ja) 2020-09-02
UA120437C2 (uk) 2019-12-10
SA521421115B1 (ar) 2022-03-01
CA2965379A1 (en) 2016-04-28
FIC20230014I1 (fi) 2023-03-31
CN111454290A (zh) 2020-07-28
EP3209302B1 (en) 2019-04-24
NZ730996A (en) 2024-04-26
JP6932227B2 (ja) 2021-09-08
US10174061B2 (en) 2019-01-08
JP2020189864A (ja) 2020-11-26
MY189519A (en) 2022-02-16
SG11201703170RA (en) 2017-05-30
IL251829B (en) 2019-09-26
CN111362980B (zh) 2022-10-18
PH12017500746A1 (en) 2017-10-30
NL301224I2 (nl) 2023-08-16
IL251829A0 (en) 2017-06-29
JP2019218356A (ja) 2019-12-26
ZA201702760B (en) 2022-05-25
KR20230066484A (ko) 2023-05-15
TW202131931A (zh) 2021-09-01
US20190375770A1 (en) 2019-12-12
JP2023174770A (ja) 2023-12-08
US9446059B2 (en) 2016-09-20
CY2023010I2 (el) 2023-06-09
NZ769153A (en) 2024-04-26
PH12017500746B1 (en) 2017-10-30
AU2015335941A1 (en) 2017-05-04
PL3209302T3 (pl) 2019-10-31
AU2015335941B2 (en) 2021-04-01
US20220153765A1 (en) 2022-05-19
AU2021201414A1 (en) 2021-03-25
AU2023210650A1 (en) 2023-08-24
BR112017008198B1 (pt) 2021-02-09
CN111454290B (zh) 2022-12-23
CN111362980A (zh) 2020-07-03
HUS2300009I1 (hu) 2023-03-28
IL268885A (en) 2019-10-31
LT3209302T (lt) 2019-06-10
US11091507B2 (en) 2021-08-17
EP3209302A1 (en) 2017-08-30
PT3209302T (pt) 2019-07-19

Similar Documents

Publication Publication Date Title
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
EP4295909A3 (en) Carbidopa and l-dopa prodrugs and methods of use
BR112018073384A2 (pt) polinucleotídeos moduladores
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
IN2013MU02576A (pt)
BR112016028081A2 (pt) Novos compostos como agentes antituberculares
BR112016026422A2 (pt) solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson
BR112019007214A2 (pt) composições do apilimode e métodos para uso do mesmo no tratamento do mal de alzheimer
BR112018077112A2 (pt) uso de liso-gb1 como alvo capaz de ser modulado por um fármaco
AR102995A1 (es) Uso de ligandos del receptor sigma en la osteoartritis
BR112018005943A2 (pt) formulações de aminoácidos de administração oral com liberação modificada
IN2013MU02575A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/10/2015, OBSERVADAS AS CONDICOES LEGAIS.